Fuller & Thaler Asset Management Inc. Buys 391,660 Shares of Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Fuller & Thaler Asset Management Inc. has increased its stake in Jazz Pharmaceuticals PLC by 41.7%, holding approximately 2.16% of the company with a value of $165.25 million.
• Multiple institutional investors have also raised their positions in Jazz Pharmaceuticals, including Wellington Management Group, which increased its ownership by 141.5%.
• Jazz Pharmaceuticals recently posted quarterly earnings that were below analysts' expectations, reporting a loss of ($8.25) earnings per share compared to the consensus estimate of ($5.61).

Fuller & Thaler Asset Management Inc. boosted its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 41.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,331,011 shares of the specialty pharmaceutical company's stock after purchasing an additional 391,660 shares during the quarter. Fuller & Thaler Asset Management Inc. owned about 2.16% of Jazz Pharmaceuticals worth $165,245,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Versant Capital Management Inc lifted its stake in Jazz Pharmaceuticals by 9.4% during the 1st quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company's stock valued at $131,000 after acquiring an additional 91 shares in the last quarter. Kendall Capital Management raised its stake in shares of Jazz Pharmaceuticals by 1.2% during the 1st quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company's stock worth $989,000 after purchasing an additional 95 shares during the period. Quarry LP raised its stake in shares of Jazz Pharmaceuticals by 6.3% during the 4th quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company's stock worth $209,000 after purchasing an additional 100 shares during the period. Louisiana State Employees Retirement System raised its stake in shares of Jazz Pharmaceuticals by 0.6% during the 1st quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company's stock worth $2,098,000 after purchasing an additional 100 shares during the period. Finally, Sound View Wealth Advisors Group LLC raised its stake in shares of Jazz Pharmaceuticals by 1.3% during the 1st quarter. Sound View Wealth Advisors Group LLC now owns 8,425 shares of the specialty pharmaceutical company's stock worth $1,046,000 after purchasing an additional 110 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the company's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the sale, the chief executive officer directly owned 436,973 shares in the company, valued at $47,031,403.99. This represents a 0.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 4.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of recent analyst reports. Piper Sandler reiterated an "overweight" rating and set a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Wall Street Zen cut Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Royal Bank Of Canada lowered their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft initiated coverage on Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a "buy" rating and a $152.00 target price on the stock. Finally, Robert W. Baird lowered their target price on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Thirteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $181.43.

Jazz Pharmaceuticals Stock Performance

JAZZ traded up $2.58 during trading hours on Friday, hitting $123.11. The stock had a trading volume of 725,096 shares, compared to its average volume of 956,746. The company's fifty day simple moving average is $112.44 and its 200 day simple moving average is $117.14. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The stock has a market cap of $7.47 billion, a PE ratio of -18.29, a price-to-earnings-growth ratio of 7.50 and a beta of 0.34. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. During the same period last year, the business posted $5.30 EPS. The company's revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.